Search Results for: teva pharmaceuticals

November 27, 2014 | Teva Pharmaceutical Industries announced that the board of directors has elected Professor Yitzhak Peterburg as chairman, becoming effective on January 1, 2015. Prof. Peterburg has been a member of the board since 2012 and will replace Dr. Phillip Frost. In addition, the board appointed Dr. Sol J. Barer to the position […]

Israeli pharmaceutical giant Teva has agreed to establish a joint venture with South Korean pharmaceutical company Handok. Teva will have a 51 percent stake in the venture, and will be in charge of manufacturing and supplying medicine. Handok will market, sell and distribute the products. The South Korean pharmaceutical market is estimated to be worth […]

Israeli pharma giant Teva Pharmaceuticals has announced that its migraine treatment AJOVY has been found to also reduce symptoms of depression. AJOVY halts the activity of the protein CGRP, which causes inflammation and the widening of blood vessels in the brain. At the onset of a migraine, an individual has high levels of CGRP in […]

Cannbit-Tikun Olam Pharmaceuticals will produce medical cannabis products for Teva Israel, to be administered as oils rich in THC and CBD.

The Israeli pharmaceutical giant says it will send some 6 million tablets of hydroxychloroquine sulfate, an FDA-approved malaria drug, to US hospitals.

The Israeli pharmaceutical giant signed separate agreements with the universities for innovative drug research and development with a focus on cancer treatments.

Teva's is the first generic naloxone hydrochloride nasal spray approved by the FDA.

 September 21, 2016 | Israeli pharmaceutical giant Teva Pharmaceutical and Regeneron Pharmaceuticals, Inc. announced an agreement to develop and commercialize pain drug fasinumab. This is Regeneron’s investigational NGF antibody in Phase III clinical development for osteoarthritis pain and in Phase II development for chronic lower back pain. Under the terms of the agreement, Teva will pay […]

December 8, 2015 | Teva Pharmaceutical Industries and Eagle Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients […]

July 26, 2015 | Israeli pharmaceuticals giant Teva is in talks to acquire Allergan’s generic drug business for $45 billion, according to a Wall Street Journal report. The deal is expected to close tomorrow. Headquartered in Dublin, Ireland, Allergan is a global pharmaceutical company. Teva was originally founded in 1901 as Salomon, Levin, and Elstein.

May 6, 2015 | Teva Pharmaceutical Industries announced that it has completed its acquisition of Auspex Pharmaceuticals for $3.2 billion. Teva will acquire Auspex at $101.00 per share with hopes that the acquisition will increase Teva’s revenue and central nervous system franchise. Teva was founded in 1901 and is currently headed by CEO and President […]

March 30, 2015 | Israeli pharmaceutical giant Teva Pharmaceutical Industries has agreed to acquire Auspex Pharmaceuticals for $3.5 billion. The acquisition will strengthen Teva’s portfolio of treatments for the central nervous system. Teva was originally founded in 1901 as Salomon, Levin, and Elstein.

January 7, 2015 | Teva Pharmaceutical Industries received US Food & Drug Administration approval for the launch of a generic equivalent to Diovan, a drug used to treat high blood pressure by heart disease patients. Diovan is marketed by Novartis Pharmaceuticals and saw sales of up to $1.8 million in the US last year. In […]

December 3, 2014 | Teva Pharmaceutical Industries launched a generic equivalent of its Exforge HCT tablets in the United States, a treatment for high blood pressure. Teva was the first company to file for the generic version, and the product will be eligible for 180 days of marketing exclusivity. Exforge HCT is marketed by Novartis […]

August 27, 2014 | Teva Pharmaceuticals and Indian company Venus Remedies entered into a collaborative agreement for the sale of an anti-cancer drug in the Canadian market. According to the agreement, Venus Remedies will manufacture the drug and will assist Teva in registering the drug in Canada. Venus will also use its manufacturing capabilities to […]